Clinical outcome of gastric cancer patients with bone marrow metastases.

The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Eur Urol (2013) 2.21

Diagnosis and management of hyponatremia in cancer patients. Oncologist (2012) 1.47

Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. Br J Cancer (2010) 0.98

Clinical outcome of gastric cancer patients with bone marrow metastases. Cancer Res Treat (2011) 0.95

Serum Natrium Determines Outcome of Treatment of Advanced GIST with Imatinib: A Retrospective Study of 80 Patients from a Single Institution. ISRN Oncol (2011) 0.87

Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma. Support Care Cancer (2014) 0.85

Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. Support Care Cancer (2015) 0.85

Case report of very late gastric cancer recurrence. Curr Oncol (2013) 0.83

Surgery for Liver Metastases From Gastric Cancer: A Meta-Analysis of Observational Studies. Medicine (Baltimore) (2015) 0.83

Gastric carcinoma with bone marrow metastasis: a case series. J Gastric Cancer (2014) 0.82

Development and Validation of a Prognostic Score to Predict Survival in Adult Patients With Solid Tumors and Bone Marrow Metastases. Medicine (Baltimore) (2015) 0.82

SOX2 inhibits metastasis in gastric cancer. J Cancer Res Clin Oncol (2016) 0.82

Recent aspects for disseminated carcinomatosis of the bone marrow associated with gastric cancer: What has been done for the past, and what will be needed in future? World J Gastroenterol (2015) 0.81

Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy. Oncotarget (2016) 0.80

Bone marrow infiltration as the initial presentation of gastric signet ring cell adenocarcinoma. J Gastrointest Oncol (2014) 0.79

Infiltrating mast cells correlate with angiogenesis in bone metastases from gastric cancer patients. Int J Mol Sci (2015) 0.79

Hyponatremia as a powerful prognostic predictor for Japanese patients with clear cell renal cell carcinoma treated with a tyrosine kinase inhibitor. Int J Clin Oncol (2014) 0.77

Targeting mast cells in gastric cancer with special reference to bone metastases. World J Gastroenterol (2015) 0.77

Pancytopenia and isolated bone marrow recurrence in a case of previously resected gastric carcinoma: a rare finding. Indian J Hematol Blood Transfus (2014) 0.75

Her-2 positive gastric cancer presented with thrombocytopenia and skin involvement: a case report. Case Rep Oncol Med (2014) 0.75

Clinical outcomes and prognostic factors for gastric cancer patients with bone metastasis. World J Surg Oncol (2017) 0.75

A rare initial presentation of gastric cancer with multiple osteolytic lesions. Case Rep Oncol Med (2015) 0.75

A case of disseminated carcinomatosis of the bone marrow originating from gastric cancer 3 years after intraperitoneal chemotherapy against peritoneal carcinomatosis. World J Surg Oncol (2016) 0.75

Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials. Cancer Med (2017) 0.75

Recurrent gastric cancer metastasizing to the bone marrow: A case report of a rare presentation. Int J Surg Case Rep (2017) 0.75

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol (2011) 6.18

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86

Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol (2011) 4.11

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol (2013) 3.53

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol (2012) 3.44

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol (2011) 3.44

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol (2013) 3.31

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 2.89

Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol (2003) 2.64

New anatomical insights on the course and branching patterns of the facial artery: clinical implications of injectable treatments to the nasolabial fold and nasojugal groove. Plast Reconstr Surg (2014) 2.61

Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol (2013) 2.44

An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys (2005) 2.19

Extrapulmonary small-cell carcinoma: a single-institution experience. Jpn J Clin Oncol (2004) 2.02

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol (2012) 1.98

Clinical Implications of the Extension of Platysmal Fibers on the Middle and Lower Face. Plast Reconstr Surg (2016) 1.94

Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk Lymphoma (2009) 1.83

Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst (2011) 1.77

The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood (2007) 1.74

Primary pulmonary non-Hodgkin's lymphoma. Jpn J Clin Oncol (2004) 1.70

Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep (2011) 1.66

Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. Ann Hematol (2007) 1.65

Novel interleukin 1beta polymorphism increased the risk of gastric cancer in a Korean population. J Gastroenterol (2004) 1.65

Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma. Leuk Res (2006) 1.60

A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer (2006) 1.56

Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Gastroenterology (2010) 1.55

Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Res Treat (2009) 1.51

Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol (2009) 1.50

Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors. Onkologie (2011) 1.47

Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer (2013) 1.43

The risorius muscle: anatomic considerations with reference to botulinum neurotoxin injection for masseteric hypertrophy. Dermatol Surg (2014) 1.43

Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer (2007) 1.42

Which patients benefit from preoperative chemoradiotherapy for intermediate staged rectal cancer? Onkologie (2011) 1.42

The anatomical origin and course of the angular artery regarding its clinical implications. Dermatol Surg (2014) 1.41

Reliability of two different presurgical preparation methods for implant dentistry based on panoramic radiography and cone-beam computed tomography in cadavers. J Periodontal Implant Sci (2012) 1.36

Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol (2002) 1.34

High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS One (2012) 1.32

Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy. BMC Cancer (2009) 1.31

Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol Cancer Ther (2011) 1.31

Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer (2005) 1.28

Microanatomy of the incisive canal using three-dimensional reconstruction of microCT images: an ex vivo study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2009) 1.28

Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res (2012) 1.27

Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma. Hepatology (2013) 1.26

MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol (2013) 1.25

Gastric leptomeningeal carcinomatosis: multi-center retrospective analysis of 54 cases. World J Gastroenterol (2009) 1.24

Location of the mandibular canal and the topography of its neurovascular structures. J Craniofac Surg (2009) 1.23

Interactions between Shh, Sostdc1 and Wnt signaling and a new feedback loop for spatial patterning of the teeth. Development (2011) 1.21

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer (2012) 1.21

Branching patterns and intraosseous course of the mental nerve. J Oral Maxillofac Surg (2007) 1.18